SARS-CoV-2 Variants
Since emerging in 2019, SARS-CoV-2’s genome has proved to be relatively stable. However, the emergence of multiple new variants in late 2020 has caused concern over the efficacy of recently-developed countermeasures, including diagnostics, therapeutics and vaccines. Many mutations have occurred in the Spike protein and its receptor-binding domain (RBD), which plays a central role in pathogenesis and the induction of neutralising antibodies. To identify and investigate the effects of these mutations, extensive work is now underway. Click here to see our full coronavirus range.
Our Spike Mutants
To support the investigation of SARS-CoV-2 variants, The Native Antigen Company offers a growing range of mutant Spike antigens. Expressed from our proprietary mammalian expression system, these antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications. For more information on our available products, click the green text in the far-right column below:
Custom Services
The Native Antigen Company also offers services to develop custom variants via site-directed mutagenesis, including the ablation of specific glycans. For multiple, or more substantial mutations such as indels, we are able to develop antigens de novo. For the investigation of mutant binding, we also offer recombinant ACE2 proteins and services to raise monoclonal and polyclonal antibodies with mutant antigens. To get in touch with a member of our R&D team, click the button below:
Spike Mutation Map
The map below shows all the Spike mutations we currently provide or are developing in relation to the original Wuhan-Hu-1 sequence:
